Mesa Laboratories, Inc. filed its Form 10-Q with the SEC on August 10, 2026, covering the quarterly period ended June 30, 2026, and reporting net income of $2,830 thousand on revenue of $60,138 thousand.

Key Highlights

  • Revenue: $60,138 thousand for the three months ended June 30, 2026, compared to $59,543 thousand in the prior-year period.
  • Net income: $2,830 thousand, down from $4,742 thousand in the three months ended June 30, 2025.
  • Diluted EPS: $0.49 per share, versus $0.85 per share in the comparable prior-year quarter.
  • Operating income: $7,031 thousand, compared to $3,064 thousand in the prior-year quarter.
  • Cash from operations: $14,736 thousand for the quarter, up from $1,893 thousand in the prior-year period.
  • Total debt reduced: The revolving line of credit decreased to $77,250 thousand from $84,500 thousand at March 31, 2026.
  • Shares outstanding: 5,595,869 shares of common stock as of August 3, 2026.

Mesa Laboratories Reports Higher Operating Income Despite Lower Net Income in June 2026 Quarter

According to the filing, Mesa Laboratories, Inc. (Nasdaq: MLAB) reported revenue of $60,138 thousand for the three months ended June 30, 2026, a modest increase from $59,543 thousand in the same quarter of the prior year. Gross profit rose to $39,012 thousand from $36,939 thousand, and total operating expenses declined to $31,981 thousand from $33,875 thousand, producing operating income of $7,031 thousand versus $3,064 thousand a year earlier.

The filing disclosed that net income for the quarter was $2,830 thousand, compared to $4,742 thousand in the three months ended June 30, 2025. The company reported that non-operating expenses for the current quarter totaled $2,678 thousand, while the prior-year period included non-operating income of $3,948 thousand, a difference the filing attributes in part to "Other expense (income), net" of $315 thousand in the current period versus income of $6,146 thousand in the prior-year period. Income tax expense was $1,523 thousand, down from $2,270 thousand. Basic earnings per share were $0.49 diluted, compared to $0.85 diluted in the prior-year quarter.

On the balance sheet, total assets were $419,224 thousand as of June 30, 2026, compared to $427,747 thousand at March 31, 2026. Cash and cash equivalents increased to $30,695 thousand from $26,928 thousand at quarter-start, supported by net cash provided by operating activities of $14,736 thousand. The company repaid a net $8,656 thousand of debt during the quarter, with the revolving line of credit reduced to $77,250 thousand. Total stockholders' equity was $188,760 thousand at June 30, 2026. The company paid dividends of $0.16 per share, totaling $884 thousand, during the quarter.

What Was Disclosed

Mesa Laboratories filed its quarterly report for the period ended June 30, 2026, disclosing revenue, income, balance sheet, and cash flow figures. Operating income improved year-over-year while net income declined, primarily reflecting changes in non-operating items.